Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
ReceptorPharma AB
AB
Bankrupt
Org 5591329833
Other research and experimental development on natural sciences and engineering
·
NACE 7219
Est. 2017 · 8 years old
1 employees
Monitor
Share
Sweden
/
Companies
/
Other research and experimental development on natural sciences and engineering
/
ReceptorPharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
2019: 0M
0M
2019
2020: 0M
0M
2020
EBITDA
SEK millions
0M
0M
0M
-1M
-1M
2019: 0M
0M
2019
2020: 0M
0M
2020
Income statement
SEK thousands
Item
2020
2019
Revenue
0
0
Staff expenses
—
—
EBITDA
−178
−223
Depreciation & amort.
−0
−0
EBIT
−178
−223
Net financials
−1
—
Profit before tax
−179
−223
Tax
−0
−0
Net profit
−179
−223
Balance sheet
SEK thousands
Item
2020
2019
Total assets
18
26
Equity
−569
−390
Long-term debt
0
0
Short-term debt
587
415
Total debt
587
415
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2019
2020
Equity ratio
<−999 %
This company
38,2 %
Market median
This company
Market median
>999% below market
2019
2020
Return on equity
—
This company
18,4 %
Market median
This company
Market median
2019
2020
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2019
2020
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2019
2020
Debt / equity
—
This company
0,62×
Market median
This company
Market median
2019
2020
Annual reports & filings
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
View
PDF
More on ReceptorPharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
